0001564590-21-049880.txt : 20211004 0001564590-21-049880.hdr.sgml : 20211004 20211004070330 ACCESSION NUMBER: 0001564590-21-049880 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211004 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211004 DATE AS OF CHANGE: 20211004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 211300983 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 8-K 1 xene-8k_20211004.htm 8-K xene-8k_20211004.htm
false 0001582313 0001582313 2021-10-04 2021-10-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2021

 

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

 

V5G 4W8

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Shares, without par value

 

XENE

 

The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 


 

 

 

Item 8.01

Other Events

On October 4, 2021, Xenon Pharmaceuticals Inc. (the “Company”) issued a press release announcing topline results from its Phase 2b ‘X-TOLE’ clinical trial, which was designed as a randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as an adjunctive treatment for adult patients with focal epilepsy.  A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit Number

Description

99.1

Press Release issued by Xenon Pharmaceuticals Inc. dated October 4, 2021.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

XENON PHARMACEUTICALS INC.

 

 

 

 

Date:  October 4, 2021

 

By:

/s/ Sherry Aulin

 

 

 

Sherry Aulin

 

 

 

Chief Financial Officer

 

 

EX-99.1 2 xene-ex991_6.htm EX-99.1 xene-ex991_6.htm

Exhibit 99.1

NEWS RELEASE

Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

 

All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups

 

Xenon to Host Conference Call and Live Webcast Today at 7:30 am Eastern Time

 

BURNABY, British Columbia, October 4, 2021 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 – a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.

 

The trial met its primary efficacy endpoint with XEN1101 demonstrating a statistically significant and dose-dependent reduction from baseline in monthly (defined as 28 days) focal seizure frequency when compared to placebo (monotonic dose response; p<0.001). Additional primary and secondary measures included a pairwise comparison of each active dose to placebo and a responder analysis with the proportion of patients who achieved a 50% or greater reduction in monthly focal seizure frequency from baseline. These results are shown in the following table; all p-values are 2-sided comparing the active dose to placebo:

 

 

XEN1101 25 mg

(N=112)

XEN1101 20 mg

(N=51)

XEN1101 10mg

(N=46)

Placebo

(N=114)

Median Reduction from Baseline in Monthly Focal Seizure Frequency

52.8%

(p<0.001)

46.4%

(p<0.001)

33.2%

(p=0.035)

18.2%

Patients with at least a 50% Reduction in Monthly Focal Seizure Frequency from Baseline

54.5%

(p<0.001)

43.1%

(p<0.001)

28.3%

(p=0.037)

14.9%

 

Jacqueline A. French, MD, Professor in the Department of Neurology at NYU Langone Health and Co-director of Epilepsy Clinical Trials at NYU Langone's Comprehensive Epilepsy Center; Founder/Director of the Epilepsy Study Consortium; and Chair of the XEN1101 X-TOLE Steering Committee, stated, “Many patients today are living with the debilitating impacts of focal seizures, even while taking multiple anti-seizure medications, so there is a substantial need for new, efficacious and well-tolerated therapies. The X-TOLE results generated from this large, multicenter, controlled trial are truly exciting because they demonstrate impressive efficacy of XEN1101 for adult patients with focal epilepsy, including those with seizures that are deemed difficult to treat. In addition, physicians and patients could benefit from XEN1101’s other important attributes, such as once-a-day dosing in the evening with no titration. With its unique potassium channel mechanism-of-action, the strength of these topline data suggest XEN1101 could play an important role in treating focal epilepsy.”

 

Dr. Christopher Kenney, Xenon’s Chief Medical Officer commented, “On behalf of the entire Xenon team, I wish to extend our thanks to the patients, investigators, and site coordinators who participated in the X-TOLE study. We have generated strong evidence that supports the efficacy, safety and tolerability of XEN1101 and depicts a highly favorable product profile for XEN1101. Importantly, we saw statistically significant reductions of focal onset seizures compared to placebo across all dose groups, which suggests it is highly active in the central nervous system. With these compelling topline results, we are eager to work with the FDA to plan for an expedited development path moving forward.”

 


 

Designed as a randomized, double-blind, placebo-controlled, multicenter study, the Phase 2b X-TOLE clinical trial evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as once-daily adjunctive treatment in adult patients with focal epilepsy. The study included a total of 325 randomized and treated subjects in the safety population and 323 subjects in the modified intent to treat population for the efficacy analyses. Subjects had an average age of 40.8 ± 13.3 years, and 8.9%, 40.3%, or 50.8% of the subjects were on and continued taking one, two, or three stable background anti-seizure medications (ASMs) throughout the study, respectively, and failed a median of 6 previous ASMs prior to study entry. The median baseline seizure frequency across the study groups was approximately 13.5 per month. Of the 285 subjects who completed the double-blind period, 96.5% entered the open-label extension to evaluate the long-term safety, tolerability, and effectiveness of XEN1101.

 

Summary of Results

 

Key Efficacy Findings:

 

 

The primary objective of the study was to assess the dose response trend of XEN1101 in reducing monthly focal seizure frequency, based on a ranked ANCOVA model. The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. The monotonic dose response relationship between the XEN1101 active dose groups compared to placebo was statistically significant (p<0.001). These data demonstrated a highly statistically significant dose-response relationship for XEN1101 in the adjunctive treatment of focal seizures in adult patients with a history of difficult-to-treat seizures.

 

 

In addition, XEN1101 demonstrated a statistically significant reduction from baseline in monthly focal seizure frequency in pairwise comparisons to placebo for all three XEN1101 doses. The median percent reduction in monthly focal seizure frequency was 52.8% in the XEN1101 25 mg group, 46.4% in the XEN1101 20 mg group, and 33.2% in the XEN1101 10 mg group compared to 18.2% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.035 for 10 mg vs. placebo.

 

 

A key secondary endpoint of the study was a responder analysis, which compared the proportion of study subjects treated with XEN1101 who achieved a ≥50% reduction in monthly focal seizures versus placebo. The percentage of subjects who achieved a >50% reduction in monthly focal seizures was 54.5% in the XEN1101 25 mg group, 43.1% in the XEN1101 20 mg group, and 28.3% in the XEN1101 10 mg group compared to 14.9% in the placebo group. Statistical significance was achieved for all dose groups compared to placebo with 2-sided p-values of p<0.001 for 25 mg vs. placebo, p<0.001 for 20 mg vs. placebo, and p=0.037 for 10 mg vs placebo.

 

 

These marked reductions in seizures were associated with statistically significant improvements in overall status, as assessed by physicians using the Clinical Global Impression of Change (CGI-C) and by subject self-reporting using  the Patient Global Impression of Change (PGI-C) scales in the XEN1101 25 mg group, which are shown in the table below with 2-sided p-values:

 

 

XEN1101 25 mg

(N=112)

Placebo

(N=114)

CGI-C (Portion of Patients Much Improved or Very Much Improved)

46.4%

(p<0.001)

22.8%

PGI-C (Portion of Patients Much Improved or Very Much Improved)

42.9%

(p=0.001)

21.9%

 

In addition to the statistically significant CGI-C and PGI-C in the XEN1101 25 mg group, the XEN1101 20 mg group was statistically significant in PGI-C, while the XEN1101 20 mg group in CGI-C and the XEN1101 10 mg group for both CGI-C and PGI-C showed numerical improvements over placebo but were not statistically significant.

 


 

Key Safety and Tolerability Findings

 

 

XEN1101 was generally well-tolerated in this study with adverse events (AEs) consistent with other ASMs.  The incidence of treatment-emergent adverse events (TEAEs) was higher in the treatment groups as compared to the placebo group, with 62.3% of patients in the placebo group, 67.4% of patients in the XEN1101 10 mg group, 68.6% of patients in the XEN1101 20 mg group, and 85.1% of patients in the XEN1101 25 mg group experiencing at least one TEAE. The most common TEAEs across all XEN1101 dose groups (n=211) were dizziness (n=52, 24.6%), somnolence (n=33, 15.6%), fatigue (n=23, 10.9%), and headache (n=21, 10.0%). Two TEAEs of urinary retention were reported in the active treatment groups, one of which required a dose reduction, and both subjects remained on drug with no other changes or intervention. Electrocardiogram (ECG) interval changes were infrequent and evenly balanced between placebo and active treatment groups. There have been no TEAEs of pigmentary abnormalities reported during the double-blind phase of the study or in preliminary analysis during the ongoing open-label extension to date with approximately 70 subjects now treated more than 12 months.

 

 

The incidence of treatment-emergent serious adverse events (SAEs) was similar in all four arms of the study with 2.6% of patients in the placebo group, 4.3% of patients in the XEN1101 10 mg group, 3.9% of patients in the XEN1101 20 mg group, and 2.6% of patients in the XEN1101 25 mg group experiencing at least one treatment-emergent SAE.

 

 

There were 3.5% of subjects in the placebo group, 2.2% of subjects in the XEN1101 10 mg group, 13.7% of subjects in the XEN1101 20 mg group, and 15.8% of subjects in the XEN1101 25 mg group that had an AE leading to treatment discontinuation.

 

Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We believe that the X-TOLE topline data support a very attractive clinical profile for XEN1101 with desirable attributes that help differentiate it from other ASMs and suggest XEN1101 could be highly competitive in the future adult focal seizure market. Of importance, the XEN1101 efficacy data are especially compelling given that approximately 50% of the subjects in X-TOLE were using three concomitant ASMs, suggesting that this was potentially an even more challenging patient population than previous studies with other ASMs.  Additionally, these data signal activity of XEN1101 in the central nervous system, which further supports our plans to develop XEN1101 in other indications, including major depressive disorder and other types of epilepsy.”

 

Xenon intends to gather input from the U.S. Food and Drug Administration and other regulatory agencies to continue planning the future clinical development of XEN1101. In addition, the X-TOLE open-label extension, which has been expanded to three years, is expected to generate important long-term data for XEN1101.

 

Conference Call Information

Xenon will host a conference call and live webcast with slides today at 7:30 am Eastern Time (4:30 am Pacific Time) to discuss the topline results from the XEN1101 Phase 2b X-TOLE clinical trial. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713.

About Xenon Pharmaceuticals Inc.

 

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

 


 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN1101; the anticipated initiation of future clinical trials for XEN1101; the timing and results of our planned interactions with regulators regarding XEN1101; and our ability to successfully develop and obtain regulatory approval of XEN1101. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; any of our or our collaborators’ product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators’ clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; impact of new or changing laws and regulations; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

 

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

 

Media/Investors Contact:

Maria McClean / Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604-484-3353 / 469-743-1834
Email: investors@xenon-pharma.com

 

GRAPHIC 3 g1ex51tngowu000001.jpg GRAPHIC begin 644 g1ex51tngowu000001.jpg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end EX-101.SCH 4 xene-20211004.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 xene-20211004_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Country Entity Address Country Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 xene-20211004_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 xene-8k_20211004_htm.xml IDEA: XBRL DOCUMENT 0001582313 2021-10-04 2021-10-04 false 0001582313 8-K 2021-10-04 XENON PHARMACEUTICALS INC. Z4 001-36687 98-0661854 200-3650 Gilmore Way Burnaby BC CA V5G 4W8 604 484-3300 false false false false Common Shares, without par value XENE NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 04, 2021
Entity Registrant Name XENON PHARMACEUTICALS INC.
Entity Central Index Key 0001582313
Entity Emerging Growth Company false
Entity File Number 001-36687
Entity Incorporation, State or Country Code Z4
Entity Tax Identification Number 98-0661854
Entity Address, Address Line One 200-3650 Gilmore Way
Entity Address, City or Town Burnaby
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5G 4W8
City Area Code 604
Local Phone Number 484-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol XENE
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports xene-8k_20211004.htm xene-20211004.xsd xene-20211004_lab.xml xene-20211004_pre.xml xene-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xene-8k_20211004.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "xene-8k_20211004.htm" ] }, "labelLink": { "local": [ "xene-20211004_lab.xml" ] }, "presentationLink": { "local": [ "xene-20211004_pre.xml" ] }, "schema": { "local": [ "xene-20211004.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xene", "nsuri": "http://www.xenon-pharma.com/20211004", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "xene-8k_20211004.htm", "contextRef": "C_0001582313_20211004_20211004", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "xene-8k_20211004.htm", "contextRef": "C_0001582313_20211004_20211004", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.xenon-pharma.com/20211004/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-049880-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-049880-xbrl.zip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end